ArticleJournal of stem cell research & therapy2013
Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction.
Article in Journal of stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cell therapy for central nervous system disorders: Current obstacles to progress.CNS neuroscience & therapeutics · 2020Review
- Drug-like delivery methods of stem cells as biologics for stroke.Expert opinion on drug delivery · 2019Review
- Upcycling umbilical cords: bridging regenerative medicine with neonatology.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2019Review
- Therapeutic potential of mesenchymal stem cells for diabetes.Journal of molecular endocrinology · 2017Review
- Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).Stem cell research & therapy · 2016Review
- The hematopoietic system in the context of regenerative medicine.Methods (San Diego, Calif.) · 2016Review
- Mesenchymal Stem Cells and Mononuclear Cells From Cord Blood: Cotransplantation Provides a Better Effect in Treating Myocardial Infarction.Stem cells translational medicine · 2016Article
- Injection of Human Cord Blood Cells With Hyaluronan Improves Postinfarction Cardiac Repair in Pigs.Stem cells translational medicine · 2016Article
- Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.Translational stroke research · 2015Article
- Cord blood processing by a novel filtration system.Cell proliferation · 2015Article
- Enhancing endogenous stem cells in the newborn via delayed umbilical cord clamping.Neural regeneration research · 2015Review
- Manipulation of a quasi-natural cell block for high-efficiency transplantation of adherent somatic cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2015Article
- Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor.Journal of neurosurgical sciences · 2014Review
- Granulocyte-colony stimulating factor and umbilical cord blood cell transplantation: Synergistic therapies for the treatment of traumatic brain injury.Brain circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Cell-based therapy is a promising therapy for myocardial infarction. Endogenous repair of the heart muscle after myocardial infarction is a challenge because adult cardiomyocytes have a limited capacity to proliferate and replace damaged cells. Pre-clinical and clinical evidence has shown that cell based therapy may promote revascularization and replacement of damaged myocytes after myocardial infarction. Adult stem cells can be harvested from different sources including bone marrow, skeletal myoblast, and human umbilical cord blood cells. The use of these cells for the repair of myocardial infarction presents various advantages over other sources of stem cells. Among these are easy harvesting, unlimited differentiation capability, and robust angiogenic potential. In this review, we discuss the milestone findings and the most recent evidence demonstrating the therapeutic efficacy and safety of the transplantation of human umbilical cord blood cells as a stand-alone therapy or in combination with gene therapy, highlighting the importance of optimizing the timing, dose and delivery methods, and a better understanding of the mechanisms of action that will guide the clinical entry of this innovative treatment for ischemic disorders, specifically myocardial infarction.
Indexed as
Identifiers
24307973PMC3845524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.